Appropriate selection of COPD patients with an eosinophilic pattern permits to add inhaled corticosteroids to bronchodilators in the right patients limiting the risk of pneumonia and to select potential patients to be treated with new monoclonal antibodies against IL-5. Here, IL5 is linked to pneumonia.